Share

    


Home / Search Results

Search Results

Search Publications

Search Again?

Filter By Content Type

Filter By Topic

Senate Insurance Committee Members talbotk@legis.la.gov sen31@legis.la.gov bouiej@legis.la.gov sen20@legis.la.gov jacksonk@legis.la.gov sen36@legis.la.gov peacockb@legis.la.gov smithgl@legis.la.gov sen27@legis.la.gov wardr@legis.la.gov
Microsoft Word - Patient Access LA_Accumulator One-Pager_2022_SB366_FINAL.docx PatientAccessLA.com | FB.com/PatientAccessLouisiana | @PatientAccessLA THE NEED Many people turn to patient assistance programs including co-pay assistance from pharmaceutical manufacturers to afford their medications. Thankfully, Senator Jimmy Harris championed a bill that successfully passed …
House Insurance Committee Members huvalm@legis.la.gov jordane@legis.la.gov hse102@legis.la.gov brownc@legis.la.gov hse090@legis.la.gov hse088@legis.la.gov hse088@legis.la.gov hse022@legis.la.gov hse074@legis.la.gov gloverc@legis.la.gov hse083@legis.la.gov hollisp@legis.la.gov hse078@legis.la.gov macks@legis.la.gov hse097@legis.la.gov mageet@legis.la.gov schexnayderc@legis.la.gov
April 5, 2022
Two thought leaders who have deep knowledge of—and experience in—biomarker testing in patients with hematologic malignancies will discuss best practices for biomarker testing in chronic lymphocytic leukemia (CLL) and multiple myeloma based on patient case discussions and the latest guidelines.
Meeting the needs of cancer program staff to ultimately improve patient outcomes is at the heart of the presidential themes of ACCC’s current and immediate past presidents. CANCER BUZZ spoke to Krista Nelson, who advocated for the professional well-being of cancer program staff and Dr. David Penberthy, who aims to leverage technology to transform cancer care delivery and the patient experience. Hear …
Microsoft Word - 2022 OSSN Resource Center Information Revised December 2021  Oncology State Society Network Resource Center Information   The Arizona Clinical Oncology Society    Nevada Oncology Society  Empire State Hematology Oncology Society   North Carolina Oncology Association  Rocky Mountain Oncology Society  South Carolina Oncology Society  Hawaii Society of Clinical …
The letter asks Congress to increase funding for this program from $20 to $60 million to approximate the level of support necessary to fund high-quality research applications and to ensure that funding is commensurate with the impact of deaths attributable to lung cancer among Veterans Health Administration patients.
The US has seen a steady decline in the overall incidence of colorectal cancer (CRC) during the past several decades. In 1975, 60 people per 100,000 were diagnosed with colorectal cancer; by 2018, that number had fallen to 34. But overall trends in CRC incidence and outcomes often differ among racial groups and geographic locations. Black Americans are more likely to be diagnosed with CRC than White …
Texas Society of Medical Oncology Educational Award for Allied Health Professionals Submission Deadline: Friday, May 6, 2022 OVERVIEW The Rocky Mountain Oncology Society (RMOS) is committed to focusing on the future of cancer care in Colorado by supporting the professional development of Allied Health Professionals in the state. The leadership of RMOS believes …
A mix-method approach to understand clinician use of biomarker testing for patients with non-small cell lung cancer.
In response to a Senate Finance Committee Hearing entitled "Prescription Drug Price Inflation: An Urgent Need to Lower Drug Prices in Medicare", ACCC submitted a statement for the record highlighting concerns with proposed drug pricing legislation.
1801 Research Boulevard, Suite 400 • Rockville, MD 20850 • T: 301.984.9496 • F: 301.770.1949 • www.accc-cancer.org March 16, 2022 The Honorable Ronald Wyden Chairman, Senate Committee on Finance 221 Dirksen Senate Office Building Washington, D.C., 20510 The Honorable Michael Crapo Ranking Member, Senate Committee on Finance 239 Dirksen Senate Office Building Washington, D.C., 20510 …
While not yet mainstream in the community setting, hear how measurable residual disease (MRD) testing has the potential to become more fully integrated into clinical practice as one of the reliable markers of treatment response for patients with multiple myeloma and chronic lymphocytic leukemia.
While recent advances in precision medicine have substantially changed the management of lung cancer, care must be taken to ensure that these advances do not worsen health disparities. This study included a case component that divided overall respondents into two cohorts to observe how patient characteristics, such as age, socio-economic status, race/ethnicity, and health literacy, affected the likelihood …
LIO-Legislative-Town-Hall-3.22.22 Leaders in Oncology Legislative Town Hall March 22, 2022 Meeting Recording: https://zoom.us/rec/share/ gz7cHJssXRDK1EPwuPODdCxt1Ss58HwRejhwvkCc7yO TB6lS08_aSKI0G7j5_RS6.o8JdTZIkuvwa2LVW Access Passcode: &57cySt. Note - Include the period at the end of password Discussion Highlights are included in the Notes Section of each slide …
Bringing CAR T–Cell Therapies to Community Oncology In recent years, chimeric antigen receptor T-cell therapy (CAR T) has emerged as an important treatment, offering the promise of disease-free survival to patients with relapsed/ refractory hematologic cancers. By attaching a chimeric antigen receptor to patients’ own T cells and then expanding these cells, CAR T-cell therapy creates a personalized …
PowerPoint Presentation Updates in Melanoma Daniel Johnson, MD Medical Oncologist Deputy Director of Precision Cancer Therapies Program T cellTumor Disclosure of Conflicts of Interest Daniel Johnson, MD, has the following financial relationships to disclose: •Speaker – Astrazeneca, BMS, Pfizer •Advisory Board/Consultant – Nektar Therapeutics Melanoma Subtypes …